Chemicals vs. drugs (Part 3): XKCD has the final word
This newsletter is part of a series — here are the links to Part 1, Part 2, (this one is Part 3), Part 4, and Part 5. You might
25 February 2020
No Comments
Summaries
Chemical vs. drugs (Part 2): How do you discriminate? / More on halicin
This newsletter is part of a series — here are the links to Part 1, (this one is Part 2), Part 3, Part 4, and Part 5. Also relevant
24 February 2020
No Comments
Chemicals vs. drugs (Part 1): The end of bacitracin / the buzz around halicin
This newsletter is the first of a series — here are the links to Part 2, Part 3, Part 4, and Part 5. You might also
21 February 2020
No Comments
In Praise of Non-Inferiority
Dear All (wonkish but intended for everybody to read and absorb): 27 Jan 2021 update: This topic now has its own YouTube video! As the
19 September 2020
No Comments
Categories of resistance: MDR, XDR, PDR, UDR, and (new!) DTR
Note: See also these related newsletters: 20 Feb 2020 (link) on DTR as part of the language of resistance and 7 June 2020 (link) on
13 January 2019
No Comments
Antibiotic supply chains: Challenges & Opportunities
Dear All, In a report entitled Understanding the Antibiotic Manufacturing Ecosystem: A view of global supply chains, pressure points, and implications for antimicrobial resistance response, the
4 May 2022
No Comments
Non-traditional antibiotics: A pipeline review and an analysis of key development challenges
Dear All, Non-traditional alternatives to antibiotics have excited a lot of interest in the past few years but we’ve seen relatively few of these progress
6 August 2019
No Comments
Vaccines to turn back the tide of antimicrobial resistance
See also This related newsletter: 14 Jul 2022, entitled “WHO Vaccine Pipeline Review; CDC On Impact Of COVID On AMR.” This 20 Oct 2024 report
29 March 2021
No Comments
Pull incentives for antibiotics: How much and why? — A review of STEDI and related literature
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), The recent discussions of the NICE/NHS England pilot subscription model (detailed newsletter plus follow-up FAQ newsletter)
14 April 2020
No Comments
All-in cost of a new antibiotic from discovery to 10 years on market
Dear All (and with thanks to Kevin Krause for co-authoring this newsletter), The elements that contribute to the all-in cost of an antibiotic have been
9 January 2021
No Comments